|
|
Vol. 16.17 – 12 September, 2025
|
|
|
|
|
|
|
|
Investigators developed and characterized genetically engineered mice with targeted knock-in of human cancer-associated FOXA1 Class 1 and Class 2 mutant transgenes. [Science]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Using a cohort of prostate cancer tissue biopsies from patients with a clinical history of at least 10 years after biopsy, scientists reported that TRPV6 expression directly correlates with CRPC tumor aggressiveness and increased risk of metastasis development.
[Signal Transduction and Targeted Therapy]
|
|
|
|
|
|
Baseline HER2 activity marks intrinsic resistance to neoadjuvant androgen deprivation therapy in localized high-risk prostate cancer and identifies a preexisting, targetable androgen receptor-low subpopulation.
[Journal of Clinical Investigation]
|
|
|
|
|
|
Through comprehensive single-cell transcriptomic profiling of enzalutamide (ENZ)-naïve and ENZ-treated tumors, scientists identified an expansion of ENZ-resistant myofibroblastic cancer-associated fibroblasts that correlates with adverse clinical outcomes. [Advanced Science]
|
|
|
|
|
|
While shed TROP2 extracellular domain did not affect prostate cancer cell proliferation and tumor growth, it increased cell migration and invasion in vitro and promoted metastatic colonization and spontaneous metastasis in vivo.
[Cancer Research]
|
|
|
|
|
|
Researchers demonstrated the therapeutic potential of disrupting interactions between the androgen receptor and its coregulator WDR77. WDR77 stimulates prostate cancer growth, and its overexpression was associated with worse patient survival. [Cell Reports]
|
|
|
|
|
|
|
|
The authors present a novel, mechanism-centered synthesis focused specifically on miRNA-mediated resistance pathways across standard treatment modalities, including androgen deprivation therapy, enzalutamide, docetaxel, and radiotherapy. [Medical Oncology]
|
|
|
|
|
|
|
|
EDAP TMS announced that the French Ministry of Health has awarded reimbursement for High Intensity Focused Ultrasound (HIFU) procedure for the treatment of prostate cancer in France. [EDAP TMS (BioSpace)]
|
|
|
|
|
|
|
|
October 22-25, 2025 Heidelberg, Germany & Online
|
|
|
|
|
|
|
|
|
|
|
King’s College London – London, England, United States
|
|
|
|
|
|
|
Henry Ford Health + Michigan State – Detroit, Michigan, United States
|
|
|
|
|
|
|
University of Michigan – Michigan, Ann Arbor, United States
|
|
|
|
|
|
|
University of Bristol – Bristol, England, United Kingdom
|
|
|
|
|
|
|
Imperial College London – London, England, United Kingdom
|
|
|
|
|
|